While grants are an effective funding mechanism for early growth companies, foundations are beginning to take larger stakes in start-ups by retaining equity or by taking a percentage of royalties from sales once the product is on the market.
- The Michael J. Fox Foundation for Parkinson’s Research has poured $170MM into Parkinson’s research, with $18.6MM into 39 industry-led projects
- FasterCures, a Maryland-based non-profit, has allocated over $500MM in foundation capital to emerging growth biotechnology companies
This phenomenon is known as Venture Philanthropy, a term coined in the 1960’s as a new means for foundations to become more actively engaged in the affairs of the grant recipient. Today, Venture Philanthropy is viewed as an investment rather than a contribution, allowing executives to to take an active role in project management and set benchmarks and goals as a condition for additional funding; in other words, Venture Philanthropy allows foundations to apply private sector models (capitalizing on efficiency, effective management, and organization) to their charitable venture.
Under the Tax Reform Act of 1969, foundations are required to give at least 5% of their yearly assets to a charitable cause or charitable purpose in order to maintain a tax-exempt status. Program Related Investments (PRIs) are a means for a foundation to invest in a forprofit or educational purpose as long as profit is not the end goal. Examples of PRIs include interest free or below-market loans, loan participations or guarantees, letters of credit, and equity investments. For foundations investing in biotech companies, royalties from cures or drug therapies can be re-invested into research or other opportunities.
For example, the Alzheimer’s Drug discovery Foundation helps fund drug discovery programs in both academia and biotechnology companies. Recognizing the major gap in funding, the ADDF proposes a larger aim on their website:
To fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early-stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of Venture Capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early-stage biotechnology companies, with investment for all of our grants based on the achievement of scientific and/or business milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research. (Alzheimers Drug Discovery Foundation.” Alzheimers Drug Discovery Foundation RSS. N.p., n.d. Web. 28 Nov. 2012.)
For the emerging growth companies, working with foundations espouses several benefits: Unlike Venture Capitalists, foundations and non-profits generally don’t have stringent terms, investment return requirements, and are a source of non-dilutive capital. Foundations have the resources to assist emerging growth healthcare companies during the clinical trial period by increasing participation through their patient networks, can help attract scientific experts to drug development program, and assist researchers in understanding the needs of the patient at an early stage.
While Venture Philanthropy has a positive outlook for future investment in emerging growth companies, the mechanism alone cannot fill the major funding gap in the biotech sector. In the coming pages, we will look to the prospect of Crowdfunding as a supplemental funding mechanism to Venture Philanthropy, strategic, and financial investments and suggest new hybrid mechanisms that can breathe new life into medical innovation.
Read our 38-page complimentary white paper on venture philanthropy: “Breathing Life Back into Biotech: Crowdfunding and the Hybridization of funding Mechanisms for Early Growth Companies.” Learn how L3C Crowdfunding can be used to raise capital from foundations and individuals with “compassionate use/charitable” intent.
If you’re running an emerging growth healthcare company, learn how to:
- Identify and Source Capital from Foundations Using L3C Crowd Finance
Investors and foundation directors will learn how to:
- Leverage HealthiosXchange’s due diligence to make the most impactful donations / investments: (HealthiosXchange ranks emerging growth healthcare companies by indication)
- Comply with IRS regulations pertaining to Program Related Investments (PRIs) and ensure IRS compliance for foundations/emerging growth companies
On April 5, 2012, President Obama signed the JOBS Act, The “Jumpstart our Business Startups Act,” H.R. 3606. The JOBS Act was the culmination of a year-long bipartisan effort in both the House and Senate to address concerns about capital formation and unduly burdensome SEC regulations. The JOBS Act enabled Equity Crowdfunding, a method of raising capital in small amounts from a large group of people using the Internet and social media.
Prior to the JOBS Act, money raised through Crowdfunding in the U.S. was relegated to micro investments or donations to causes and ventures within a framework of providing rewards including sponsorships, loans (microfinance), and gifts.
The growth in worldwide Crowdfunding volume has been astounding. In 2011, over $1.4 billion was raised through Crowdfunding with projections of $2.8 billion in 2012 (91% growth rate). Two leading U.S. based “Donation/Gift” based Crowdfunding platforms, Kickstarter and Indiegogo, have experienced exponential growth as measured by funding volume and number of deals/participants.
Crowdfunding is a big advantage for the Crowdfunders since it allows them to participate in angel investing, whose returns have outperformed over the past decade.
The Crowdfunding model is disrupting the traditional fundraising ecosystem. Research from the Angel Capital Education Foundation shows startups raise $60 million annually through friends and family, compared with $20 billion for Venture Capital and $20 billion from Angel investors. (Schroter, Wil. “Crowdfunding Streamlines the Friends and Family Round.” PandoDaily. N.p., 6 July 2012. Web. 28 Nov. 2012.) For emerging growth companies with revenues under $10 million per year, there is a huge funding gap, making it extremely difficult for business owners to get loans or credit lines from banks.
The legalization of equity crowdfunding for nonaccredited investors will allow the average American citizen (who makes less than $200,000 per year) to invest in start-up companies and widely expands the pool of potential investors for early growth companies.
The biggest question that remains is whether life sciences companies see opportunities for small scale financing within a model that requires drastically high operating costs and expectations of significant returns.
The innovation period, the time a biotechnology company needs to develop a product, can be up to a decade or more. During this time virtually all small biotech firms have not product revenue, so all product development costs must come from investors.
The Securities and Exchange Commission and FINRA, the two organizations tasked with implementing the JOBS Act, will render Equity Crowdfunding regulations in 1013/2014. Until then, Accredited investors interested in funding early-stage companies can fund private companies under current exemptions.
S. Jordan Associates has published a complimentary, informative Crowdfunding White Paper: “Life Sciences Private Placements – Is Equity Crowdfunding a Viable Financing Vehicle?”
The White Paper answers some of the most pressing questions posed by industry executives and financiers, including:
- What would need to change about Equity Crowdfunding, as it is conceived today, to make it a truly viable and complementary component of the startup capital markets?
- How can Equity Crowdfunders and Angels/Venture Capitalists work together?
- Can Equity Crowdfunding augment the traditional lifeblood of startups, Friends and Family and Angel Seed Rounds?
- When should life sciences’ companies raise Equity Crowdfunding Capital?
- What are the benefits of diversifying the investor base through Equity Crowdfunding?
- Why is $300,000 – $500,000 the most likely Crowdfunding range for life science companies?
- Why are investors with philanthropic/compassionate use goals ideal Crowdfunding investors?